Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer

Authors

Ramaswamy Govindan, Washington University School of Medicine in St. Louis
et al

Journal

Journal of Thoracic Oncology

Publication Date

2017

Volume

12

Issue

10

Inclusive Pages

1552-1560

Document Type

Open Access Publication

DOI

10.1016/j.jtho.2017.06.070

Rights and Permissions

Yang JC-H, Ou, S-HI, De Petris L, et al (2017) Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12(10):1552-1560. https://doi.org/10.1016/j.jtho.2017.06.070 Copyright 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Govindan, Ramaswamy and et al, "Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer." Journal of Thoracic Oncology. 12, 10. 1552-1560. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6923